CN115244051A - 苯并五元环类化合物 - Google Patents

苯并五元环类化合物 Download PDF

Info

Publication number
CN115244051A
CN115244051A CN202180020060.8A CN202180020060A CN115244051A CN 115244051 A CN115244051 A CN 115244051A CN 202180020060 A CN202180020060 A CN 202180020060A CN 115244051 A CN115244051 A CN 115244051A
Authority
CN
China
Prior art keywords
compound
mmol
mixture
stirred
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180020060.8A
Other languages
English (en)
Inventor
王宏健
钱文远
张明
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN115244051A publication Critical patent/CN115244051A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一类式(I)所示的苯并五元环类化合物或其药学上可接受的盐，其在抑制抗细胞凋亡Bcl‑2蛋白活性方面具有显著作用。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202180020060.8A 2020-03-12 2021-03-08 苯并五元环类化合物 Pending CN115244051A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010171071 2020-03-12
CN2020101710713 2020-03-12
PCT/CN2021/079579 WO2021180040A1 (zh) 2020-03-12 2021-03-08 苯并五元环类化合物

Publications (1)

Publication Number Publication Date
CN115244051A true CN115244051A (zh) 2022-10-25

Family

ID=77670448

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180020060.8A Pending CN115244051A (zh) 2020-03-12 2021-03-08 苯并五元环类化合物

Country Status (3)

Country Link
US (1) US20230128137A1 (zh)
CN (1) CN115244051A (zh)
WO (1) WO2021180040A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023078398A1 (en) * 2021-11-05 2023-05-11 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2 inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102282129A (zh) * 2009-01-19 2011-12-14 雅培制药有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN103153993A (zh) * 2010-05-26 2013-06-12 Abbvie公司 治疗癌症和免疫与自身免疫疾病的细胞程序死亡诱导药剂
CN103167867A (zh) * 2010-10-29 2013-06-19 Abbvie公司 含有细胞凋亡诱导药剂的固体分散体
EP3412666A1 (en) * 2017-06-07 2018-12-12 Albany Molecular Research, Inc. Process and intermediates for the preparation of bcl-2 inhibitors including venetoclax through reductive amination
CN109152933A (zh) * 2016-04-21 2019-01-04 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
CN109311871A (zh) * 2016-08-05 2019-02-05 密歇根大学董事会 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物
CN110546151A (zh) * 2017-04-18 2019-12-06 上海复尚慧创医药研究有限公司 凋亡诱导剂

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102282129A (zh) * 2009-01-19 2011-12-14 雅培制药有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN103153993A (zh) * 2010-05-26 2013-06-12 Abbvie公司 治疗癌症和免疫与自身免疫疾病的细胞程序死亡诱导药剂
CN103167867A (zh) * 2010-10-29 2013-06-19 Abbvie公司 含有细胞凋亡诱导药剂的固体分散体
CN109152933A (zh) * 2016-04-21 2019-01-04 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
CN109311871A (zh) * 2016-08-05 2019-02-05 密歇根大学董事会 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物
CN110546151A (zh) * 2017-04-18 2019-12-06 上海复尚慧创医药研究有限公司 凋亡诱导剂
EP3412666A1 (en) * 2017-06-07 2018-12-12 Albany Molecular Research, Inc. Process and intermediates for the preparation of bcl-2 inhibitors including venetoclax through reductive amination

Also Published As

Publication number Publication date
WO2021180040A1 (zh) 2021-09-16
US20230128137A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
CN111484477B (zh) 一种苯并吡啶酮杂环化合物及其用途
CN114349750A (zh) Kras突变蛋白抑制剂
JP7103952B2 (ja) Ｆｇｆｒ４阻害剤、その製造方法及び応用
CN108699035A (zh) 新化合物
KR20190034225A (ko) 거대환 키나제 억제제
JP6975791B2 (ja) メニン−ｍｌｌ相互作用のスピロ二環式阻害剤
WO2021027943A1 (zh) 哒嗪酮并嘧啶类衍生物及其医药用途
JP7088906B2 (ja) Ｆｇｆｒ４阻害剤並びにその製造方法及び使用
JP6986032B2 (ja) Ｊａｋ阻害剤としてのピロロピリミジン化合物の結晶
CN112368281B (zh) 作为pde3/pde4双重抑制剂的三并环类化合物
CN111971287A (zh) 作为trk激酶抑制剂的大环化合物
CN111440161B (zh) 一种具有par4拮抗活性的二环杂芳基类化合物及其应用
JP2022533740A (ja) メチル基及びトリフルオロメチル基を含む二置換スルファミド系選択的ｂｃｌ－２阻害剤
CN115244051A (zh) 苯并五元环类化合物
JP7418051B2 (ja) フルオロピロロピリジン系化合物及びその使用
CN115819418B (zh) Plk1激酶抑制剂及其制备方法和应用
WO2023125928A1 (zh) Menin抑制剂及其用途
JP2022539752A (ja) Ｃｃｒ２／ｃｃｒ５アンタゴニストとしてのヘテロシクロアルキル系化合物
WO2020063965A1 (zh) 作为选择性Trk抑制剂的吡唑并嘧啶衍生物
CN114008046A (zh) 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物
WO2023196517A1 (en) Cdk9 inhibitors
WO2021139814A1 (zh) 喹啉并咪唑类化合物及其应用
TW202325300A (zh) 稠合醯亞胺類衍生物及其應用
WO2021218912A1 (zh) 含苯基并内磺酰胺的化合物
TW202300485A (zh) Plk4抑制劑及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40074274

Country of ref document: HK